The PATH Study

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) The PATH Study was a trial that investigated immunoglobulin treatment infused with a pump into the tissue under the skin (subcutaneously). There are several advantage of subcutaneous over intravenous treatment, e.g. patients or their caregivers can treat themselves at home, there are less severe…

Read More

Japanese Ecuilizumab Trial for GBS

A new treatment with compliment inhibition improves motor function in Guillain- Barré syndrome: Japanese eculizumab trial for Guillain- Barré syndrome (JET-GBS) Recent basic studies on the pathophysiology of Guillain- Barré syndrome (GBS) have shown that complement activation has a major role on peripheral nerve damage in GBS. Eculizumab (Alexion Pharmaceuticals Inc) is a humanized monoclonal antibody…

Read More